Evidence map›Paper›PMID 19689750›Full record

ArticleInternational journal of stroke : official journal of the International Stroke Society2009

Erythropoietin promotes neurological recovery after intracerebral haemorrhage in rats.

D M Seyfried, Y Han, D Yang, J Ding, M Chopp

Open access · greenAbstract read
In one paragraph

Article in International journal of stroke : official journal of the International Stroke Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Erythropoietin protects against hemorrhagic blood-brain barrier disruption through the effects of aquaporin-4.Laboratory investigation; a journal of technical methods and pathology · 2014
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

D M SeyfriedDepartment of Neurosurgery, Henry Ford Health System, Detroit, MI 48202, USA. nsdos@neuro.hfh.edu
Y Han
D Yang
J Ding
M Chopp
Henry Ford Health System · US

Funding

Simvastatin treatment of experimental intracerebral hemorrhageR01NS058581 · NINDS · HENRY FORD HEALTH SYSTEM · PI SEYFRIED, DONALD M. · 2007 to 2010
$1.3M
NINDS NIH HHS R01 NS058581PHS HHS NSO58581
6 · The paper itself

Abstract

backgroundAttention has turned to neurorestorative therapies, including erythropoietin, for experimental ischaemic stroke and head injury. Treatments for intracerebral haemorrhage need to be developed, as this represents a particularly devastating and common form of neurological injury. Aim The aim of this study is to investigate the therapeutic potential of erythropoietin after intracerebral haemorrhage in rats and to measure its effects on mechanisms of recovery and neurogenesis.

methodsIntracerebral haemorrhage was induced in 24 Wistar male rats by intrastriatal infusion of autologous blood. Recombinant human erythropoietin (5000 or 10,000 U/kg BW/day) or saline was administered starting 1 day after intracerebral haemorrhage and continued daily for 1 week (n=8 for each group). To label proliferating cells, 5'-bromo-2' deoxyuridine was injected daily for 13 days after intracerebral haemorrhage. All animals survived for 2 weeks after intracerebral haemorrhage. Functional outcome, area of tissue loss and immunohistochemical staining were measured at 14 days after intracerebral haemorrhage. Global test or anova was used to test the erythropoietin dose effect.

resultsRats receiving recombinant human erythropoietin after intracerebral haemorrhage exhibited significant improvement in modified neurological severity score and corner test at 14 days (P<0.05). Increased expression of phenotypes of synaptogenesis and proliferating immature neurons were shown by immunohistochemical staining. Only the group receiving a lower dose of recombinant human erythropoietin had significantly less tissue loss compared with the control group (P<0.05). In rats treated with recombinant human erythropoietin, double staining for 5'-bromo-2' deoxyuridine and TUJ1 revealed a subpopulation of cells that express an immature neuronal marker while still dividing.

conclusionsErythropoietin improves neurological outcome and increases histochemical parameters of neurogenesis when given after intracerebral haemorrhage in rats. Intriguingly, only the lower dose of recombinant human erythropoietin was effective in reducing tissue loss in the region of intracerebral haemorrhage.

Indexed as

AnimalsAntimetabolitesBrainBromodeoxyuridineCerebral HemorrhageColoring AgentsErythropoietinHumansImmunohistochemistryIndicators and ReagentsLinear ModelsMaleNerve Tissue ProteinsPsychomotor PerformanceRatsRats, WistarAntimetabolitesBromodeoxyuridineColoring AgentsErythropoietinIndicators and ReagentsNerve Tissue ProteinsRecombinant Proteins

Identifiers

PMID19689750
PMCPMC2758569
OpenAlexW1997480516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.